我国左氧氟沙星治疗耐多药肺结核疗效的系统评价  

Effectiveness of levofloxacin for multidrug resistant pulmonary tuberculosis: a systematic review

作　　者：孙莹[1,2] 温华[1] 

机构地区：[1]中国医科大学附属第一医院呼吸内科,沈阳110001 [2]沈阳市胸科医院呼吸内科,沈阳110044

出　　处：《上海医药》2013年第11期18-22,共5页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:系统评价我国左氧氟沙星治疗耐多药肺结核的疗效。方法:计算机检索万方数据库、中国期刊全文数据库、中华医学会期刊数据库,并辅以手工检索,收集我国左氧氟沙星治疗耐多药肺结核的所有随机对照试验,检索文献发表时间为2000年至2012年。并采用Jadad量表对纳入研究进行质量评价后,用RevMan5.0软件进行荟萃分析。结果:最终纳入26个随机对照试验,合计2791例患者。荟萃分析结果显示:与对照组相比,左氧氟沙星组患者痰菌阴转、病灶吸收以及空洞闭合情况均明显高于对照组中的对氨基水杨酸异烟肼片,利福喷丁,乙胺丁醇,阿米卡星等药物。结论:左氧氟沙星治疗耐多药肺结核安全有效,但由于文献数量有限,质量较低,有待于大样本、高质量的研究进一步研究验证。Objective： To systematically evaluate the effectiveness of levofloxacin in controlling multidrug resistant tuberculosis （MDR-TB）. Methods： Literatures in databases such as Wanfang database, CNKI and Periodical database of the Chinese Medical Association from 2000 to 2012 were searched, sometimes with the aid of hand searching to collect randomized controlled trials on levofloxacin used to treat MDR-TB, in which their quality was evaluated by adopting the Jadad scale and meta-analysis was performed by RevMan 5.0 software. Results： A total of 26 RCTs involving 2791 cases were included. The results of meta-analysis showed the efficacy of levofloxacin in the sputum negative conversion rate, the focus absorption and cavity closure rate was significantly better than that of pasiniazid, rifapentine, ethambutol and amikacin as compared with the placebo group. Conclusion： Levofloxacin for the treatment of MDR-TB is safe and effective. However, because of the limited number and low quality of literatures, it may need large sample and high quality of research to be further verified.

关 键 词：左氧氟沙星 耐多药肺结核 系统评价 荟萃分析 随机对照试验 

分 类 号：R521[医药卫生—内科学] R453[医药卫生—临床医学]